2022 2022 Annual Meeting: Supporting a Patient-Centric Approach to Dose Optimization in Oncology: The Essential Role of Patient-Reported Outcomes (PROs) View PDF
2022 2022 Annual Meeting: Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Clinical Trials View PDF
2022 Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors Read more
2024 Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies Read more
2022 Circulating Tumor DNA in Development of Therapies for Cancer: An Evidentiary Roadmap to an Early Endpoint for Regulatory Decision-Making View PDF
2022 Multi-Cancer Early Detection Screening Tests: Considerations for Use of Real-World Data View PDF
